Erica Fong

机构：Spero Therapeutics (United States)

发表论文 17 篇 · 总被引 818 次 · h-index 6

代表论文

• Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial (2021 · Nature Medicine · 被引 357)
• Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2023 · ˜The œLancet. Gastroenterology & hepatology · 被引 256)
• A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis (2022 · JHEP Reports · 被引 105)
• Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2025 · The Lancet · 被引 57)
• LBO-002 Efruxifermin significantly reduced liver fibrosis in MASH patients with F2-F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study) (2024 · Journal of Hepatology · 被引 8)
• Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor (2017 · Blood · 被引 6)